Immunotherapy

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about research that demonstrated the potential of a novel vaccine as front-line maintenance therapy in advanced-stage ovarian cancer.

Nathan A. Pennell, MD, PhD, spoke with Healio about phase 3 findings from the CheckMate 816 trial presented at the virtual ASCO Annual Meeting.

Patients with cancer and overweight or obesity had better outcomes with immune checkpoint inhibitors than lighter patients, but only when they received weight-based dosing of the therapy, study results showed.

Use of alrizomadlin with pembrolizumab appeared to restore the antitumor effects of the anti-PD-1 antibody among patients with melanoma resistant to or intolerant of immunotherapy, according to phase 2 study results.

An FDA advisory panel voted 10-7 in favor of recommending approval of teplizumab to delay development of type 1 diabetes in high-risk children and adults, with most committee members expressing some concerns about trial size and safety.

Clinicians who treat vasculitides are accustomed to uncertainty. Vasculitis, in its varied forms, shares symptoms with an entire cross-section of unrelated conditions that can prompt frequent misdiagnoses and potentially fatal treatment decisions.

More than one-third of a small cohort patients with early-stage hepatocellular carcinoma achieved at least 50% tumor necrosis following neoadjuvant treatment with cemiplimab, results of a phase 2a trial showed.

The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.

Patients with KRAS wild-type, PD-L1-high non-small cell lung cancer treated with immunotherapy alone exhibited considerably shorter OS than those with a KRAS mutation, according to results in a research letter published in JAMA Oncology.

Lisa M. Coussens, PhD, FAACR, has been elected president-elect of American Association for Cancer Research for the 2021-2022 term.